Link to this page
The Drug-Drug Interactions Ontology
| Preferred Name | droxidopa | |
| Synonyms |
(2R,3S)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid C9H11NO5 |
|
| ID |
http://purl.obolibrary.org/obo/dinto_DB06262 |
|
| activates |
http://purl.obolibrary.org/obo/dinto_2907 http://purl.obolibrary.org/obo/dinto_4020 http://purl.obolibrary.org/obo/dinto_3475 http://purl.obolibrary.org/obo/dinto_3877 http://purl.obolibrary.org/obo/dinto_1843 http://purl.obolibrary.org/obo/dinto_1581 http://purl.obolibrary.org/obo/dinto_0234 |
|
| binds |
http://purl.obolibrary.org/obo/dinto_1803 http://purl.obolibrary.org/obo/dinto_2718 http://purl.obolibrary.org/obo/dinto_2907 http://purl.obolibrary.org/obo/dinto_4020 http://purl.obolibrary.org/obo/dinto_3475 http://purl.obolibrary.org/obo/dinto_3877 http://purl.obolibrary.org/obo/dinto_1843 http://purl.obolibrary.org/obo/dinto_1581 http://purl.obolibrary.org/obo/dinto_0234 http://purl.obolibrary.org/obo/dinto_3504 http://purl.obolibrary.org/obo/dinto_1135 |
|
| CASRN |
23651-95-8
|
|
| DBBrand |
dops
|
|
| DBSynonym |
droxydopa l-dops l-dihydroxyphenylserine l-threo-3,4-dihydroxyphenylserine
|
|
| Definition |
Droxidopa is a precursor of noradrenaline that is used in the treatment of Parkinsonism. It is approved for use in Japan and is currently in trials in the U.S. The racaemic form (dl-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated in the treatment of orthostatic hypotension. There is a deficit of noradrenaline as well as of dopamine in Parkinson s disease and it has been proposed that this underlies the sudden transient freezing seen usually in advanced disease.
|
|
| has pharmacological target |
http://purl.obolibrary.org/obo/dinto_2907 http://purl.obolibrary.org/obo/dinto_4020 http://purl.obolibrary.org/obo/dinto_3475 http://purl.obolibrary.org/obo/dinto_3877 http://purl.obolibrary.org/obo/dinto_1843 http://purl.obolibrary.org/obo/dinto_1581 http://purl.obolibrary.org/obo/dinto_0234 |
|
| InChI |
InChI=1S/C9H11NO5/c10-7(9(14)15)8(13)4-1-2-5(11)6(12)3-4/h1-3,7-8,11-13H,10H2,(H,14,15)/t7-,8+/m1/s1
|
|
| InChIKey |
InChIKey=QXWYKJLNLSIPIN-SFYZADRCSA-N
|
|
| inhibits | ||
| is metabolised by | ||
| is substrate of | ||
| is transported by | ||
| label |
droxidopa
|
|
| modulates |
http://purl.obolibrary.org/obo/dinto_2907 http://purl.obolibrary.org/obo/dinto_4020 http://purl.obolibrary.org/obo/dinto_3475 http://purl.obolibrary.org/obo/dinto_3877 http://purl.obolibrary.org/obo/dinto_1843 http://purl.obolibrary.org/obo/dinto_1581 http://purl.obolibrary.org/obo/dinto_0234 |
|
| prefixIRI |
obo2:dinto_DB06262
|
|
| prefLabel |
droxidopa
|
|
| SMILES |
N[C@H]([C@@H](O)C1=CC(O)=C(O)C=C1)C(O)=O
|
|
| Synonym |
(2R,3S)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid C9H11NO5
|
|
| xref |
PubChem Compound:443940 Wikipedia:http://en.wikipedia.org/wiki/Droxidopa ChemSpider:391994 PharmGKB:PA164748386 PubChem Substance:99443239
|
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |